【摘 要】目的：探讨对乙肝肝硬化腹水患者拟定五苓散+六味地黄丸方案治疗后获得的临床效果。方法：选择我院2017年06月～2019年05月收治的76例乙肝肝硬化腹水患者作为实验对象;数字奇偶法分组后拟定每组用药方案;参照组(38例)：拟定西医方案展开疾病治疗;实验组(38例)：拟定西医方案+五苓散+六味地黄丸展开疾病治疗;就组间症状总改善率以及血清炎症因子水平展开对比。结果：实验组乙肝肝硬化腹水患者症状总改善率(97.37%)高于参照组(81.58%)明顯(P<0.05);治疗前，实验组乙肝肝硬化腹水患者血清炎症因子水平同参照组比较差异不明显(P>0.05);治疗后，实验组血清炎症因子水平均低于参照组明显(P<0.05)。结论：乙肝肝硬化腹水患者于临床接受五苓散+六味地黄丸治疗后，利于症状总改善率提升以及血清炎症因子水平降低，最终促进乙肝肝硬化腹水患者早期转归。

【关键词】五苓散;六味地黄丸;乙肝肝硬化腹水;临床效果

【中图分类号】R622 【文献标识码】A 【文章编号】1004-7484(2019)07-0262-02

【Abstract】objective： to investigate the clinical effect of Wuling Powder Liuwei Dihuang Pill for patients with hepatitis B liver cirrhosis and ascitic fluid.Methods： from June 2017 to May 2019， 76 patients with hepatitis B cirrhotic ascitic fluid were selected as experimental subjects. After grouping with digital parity method， each group was divided into two groups： control group (38 cases)： western medicine plan was drawn up to carry out disease treatment; experimental group (38 cases)： Wuling powder Liuwei Dihuang pill was drawn up to carry out disease treatment; the total improvement rate of symptoms and the level of serum inflammatory factors were compared between the two groups.Results： the total improvement rate of symptoms in the experimental group (97.37%) was significantly higher than that in the control group (81.58%) (P < 0.05)， the level of serum inflammatory factors in the experimental group was not significantly different from that in the control group (P > 0.05)， and the level of serum inflammatory factors in the experimental group was significantly lower than that in the control group (P < 0.05).Conclusion：after clinical treatment with Wuling Powder Liuwei Dihuang Pill， the patients with hepatitis B cirrhotic ascites are beneficial to the increase of the total improvement rate of symptoms and the decrease of serum inflammatory factor level， and finally promote the early prognosis of patients with hepatitis B cirrhotic ascitic fluid.

【Keywords】WuXi powder; Liuwei Dihuang Wan; Hepatitis B liver cirrhosis ascites; Clinical effect

    乙肝肝硬化腹水作为慢性进展性肝脏疾病之一，主要因乙型病毒性肝炎表现为长时间反复发作导致，临床需拟定有效方案展开此类患者的针对性治疗，以使得患者预后效果显著改善^[1-2]。本次研究将针对乙肝肝硬化腹水患者探究拟定五苓散+六味地黄丸用药方案治疗的可行性，以利于乙肝肝硬化腹水患者的早期转归。, 百拇医药(任小兵 梁庭栋 任小菊)